The main goals of the third funding period are to better understand the molecular mechanisms of myeloid cell
diversity in the CNS and the interactions of microglia and CAMs with neurons, macroglia and vascular cells during brain development, homeostasis and disease. In detail, we want to. In detail, we want to:
explore the molecular mechanisms and environmental factors that determine myeloid cell identity in the healthy and diseased CNS (Project area A) (Area A)
examine the spatial distribution and local cellular interactions of brain myeloid cells (Project area A) (Area A)
identify the cellular mechanisms, metabolic signals and sex-dependent cues for the establishment of contextassociated microglia states and the interactions of myeloid cells with other cells in the affected CNS (Project areas A, B) (Areas A, B)
develop strategies for therapeutic targeting of myeloid cells in CNS disorders (Project area B) (Area B)
Wang M, Otto C, Fernández Zapata C, Dehlinger A, Gallaccio G, Diekmann LM, Niederschweiberer M, Schindler P, Körtvélyessy P, Kunkel D, Paul F, Ruprecht K, Böttcher C. Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics. iScience. iScience 28(5):112383; doi: 10.1016/j.isci.2025.112383 (2025).
Schaible P, Henschel J, Erny D: How the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells. J Neuroinflammation 22(1):60; doi: 10.1186/s12974-025-03371-0 (2025).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok